|
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our study shows that TTF-1 sensitizes the KRAS-mutated A549 and NCI-H460 lung cancer cells to cisplatin, a common chemotherapy used to treat lung cancer.
|
31142791 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among three driver oncogene alterations, EGFR mutation was significantly associated with the FH-PC (53.8%, 84.1%, and 65.8%, respectively; P = 0.016), ALK/ROS1/RET fusions was significantly associated with the FH-NPC (13.7%, 0.0%, and 5.0%, respectively; P = 0.004), but KRAS mutation was not associated with any type of the FH (13.8% vs. 6.0% vs. 7.8%, respectively; P = 0.288).
|
31421257 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our results confirm previous reports that EGFR mutations are more prevalent than KRAS in Chinese lung cancer patients.
|
31369215 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS-mutant lung cancers have been recalcitrant to treatments including those targeting the MAPK pathway.
|
30327306 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The median overall survival (OS) was shorter for patients with HER2-mutant (1.6 years; P < .001) or KRAS-mutant lung cancers (1.1 years; P < .001) than patients with EGFR-mutant lung cancers (3.0 years).
|
31469421 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
|
30833304 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.
|
30297358 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Activated KRAS is frequently observed and paralleled by inactivating of tumor suppressors in lung cancer, while the mechanisms remained elusive.
|
30906631 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We performed genome-scale loss-of-function CRISPR-Cas9 screens in the presence of a MEK1/2 inhibitor (MEKi) in KRAS-mutant pancreatic and lung cancer cell lines and identified genes that cooperate with MEK inhibition.
|
31577942 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The identification of dependencies borne through common co-occurring mutations are sought to more effectively target KRAS-mutant lung cancer.
|
31519898 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although the effects of the combination vary, the combined therapeutics are one of the best options at present to treat KRAS mutant lung cancer.
|
31475900 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here we show that genetic inhibition of SHOC2 suppresses tumorigenic growth in a subset of KRAS-mutant NSCLC cell lines and prominently inhibits tumour development in autochthonous murine KRAS-driven lung cancer models.
|
31182717 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Together, our results suggest that mutant KRAS promotes RAD51 expression to enhance DNA damage repair and lung cancer cell survival, suggesting that RAD51 may be an effective therapeutic target to overcome chemo/radioresistance in KRAS mutant cancers.[BMB Reports 2019; 52(2): 151-156].
|
30638176 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Collectively, these results uncover collateral vulnerabilities co-occurring with drug resistance and tumor heterogeneity, informing novel therapeutic avenues for KRAS-mutant lung cancer.
|
31431614 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The efficacy of mutant K-Ras, P53 and EGFR (Epidermal Growth Factor Receptor) peptides have been tested as cancer vaccines in pancreatic, colorectal, and lung cancers.
|
31722672 |
2019 |
|
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
The need for effective treatment of KRAS‑mutant lung cancer is an emerging issue.
|
30015929 |
2018 |
|
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
A model of K-Ras-initiated lung cancer was used to follow the transition of precancerous adenoma to adenocarcinoma.
|
29930325 |
2018 |
|
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
CTD_human |
Lung cancer cells expressing oncogenic K-Ras have bypassed the senescence barrier.
|
29247004 |
2018 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We identified clinical, demographic, and regional predictors of EGFR & KRAS testing among Medicare beneficiaries with a new diagnosis of lung cancer in 2011-2013 claims.
|
29554880 |
2018 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Caenepeel and colleagues and Ramsey and colleagues have developed two novel, potent, and selective MCL1 inhibitors that are effective against many hematologic malignancies, and Nangia and colleagues describe how one of these inhibitors can be successfully combined with BCL-xL and MEK inhibition to treat KRAS-mutated lung cancer.<i>See related article by Ramsey et al., p. 1566</i>.<i>See related article by Caenepeel et al., p. 1582</i>.<i>See related article by Nangia et al., p. 1598</i>.
|
30510014 |
2018 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes.
|
30145409 |
2018 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
SASP components tumor necrosis factor-α and intercellular adhesion molecule-1 are required for NK cell surveillance of drug-treated tumor cells, which contributes to tumor regressions and prolonged survival in a KRAS-mutant lung cancer mouse model.
|
30573629 |
2018 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We aimed to determine the prognosis of early-stage ALK-positive lung cancers relative to KRAS- and EGFR-mutant lung cancers.
|
30032847 |
2018 |
|
Malignant neoplasm of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
We review a pathway where asymmetric division of precancerous cells generates TIC in a K-Ras-initiated model of lung cancer.
|
30290712 |
2018 |
|
Malignant neoplasm of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
TaqMan probes and NGS were compared for their ability to detect EGFR and KRAS mutations, and NGS mutation profiles were analyzed on a large series of non-small-cell lung cancers (n = 1343).
|
29787863 |
2018 |